MCID: GRV001
MIFTS: 61

Graves' Disease

Categories: Endocrine diseases, Immune diseases, Rare diseases

Aliases & Classifications for Graves' Disease

MalaCards integrated aliases for Graves' Disease:

Name: Graves' Disease 12 77 54 26 15
Graves Disease 12 26 38 30 56 45 15 17 74
Exophthalmic Goiter 12 54 26
Toxic Diffuse Goiter 26 74
Basedow's Disease 12 26
Basedow Disease 54 26
Autoimmune Hyperthyroidism 26
Toxic Multinodular Goiter 74
Graves' Hyperthyroidism 54
Grave's Disease 12
Parry Disease 54

Classifications:



External Ids:

Disease Ontology 12 DOID:12361
KEGG 38 H00082
MeSH 45 D006111
NCIt 51 C3071
SNOMED-CT 69 38591003 55807009
ICD10 34 E05.0

Summaries for Graves' Disease

NIH Rare Diseases : 54 Graves' disease is an autoimmune disorder that leads to overactivity of the thyroid gland (hyperthyroidism). It is caused by the immune system mistakenly attacking the thyroid gland, causing the gland to produce too much thyroid hormone. Graves disease is the most common cause of hyperthyroidism and occurs most often in women over age 20. However, the disorder may occur at any age and can affect males as well. More common signs and symptoms of hyperthyroidism due to Graves' disease include irritability, a fast and irregular heartbeat, hand tremors, diarrhea, increased sweating, trouble sleeping, and weight loss. Some people develop abnormal enlargement of the thyroid gland (goiter). Women with Graves' disease may have irregular menstrual periods. In some cases, Graves' disease causes other problems such as Graves�?? dermopathy (a condition marked by red, swollen skin), various eye abnormalities (such as bulging eyes, vision problems, pain, or swelling), emotional or behavioral changes, heart-related complications, or bone problems (such as osteoporosis). Treatment for hyperthyroidism and its symptoms may include radioiodine therapy, antithyroid drugs, and/or thyroid surgery. Most people eventually develop hypothyroidism after treatment for hyperthryoidism; this is treated with a daily synthetic thyroid hormone pill. Graves' dermopathy may be treated with corticosteroids and/or compression wraps. Eye problems may not improve after thyroid treatment and may be treated separately with eyedrops, rituximab, or rarely, surgery or radiation therapy.

MalaCards based summary : Graves' Disease, also known as graves disease, is related to graves disease 1 and myxedema. An important gene associated with Graves' Disease is TSHR (Thyroid Stimulating Hormone Receptor), and among its related pathways/superpathways are Autoimmune thyroid disease and NF-kappaB Signaling. The drugs Propylthiouracil and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include thyroid, eye and t cells, and related phenotypes are endocrine/exocrine gland and hematopoietic system

Disease Ontology : 12 An autoimmune disease of endocrine system that involves production of excessive amount of thyroid hormones, located in thyroid gland.

Genetics Home Reference : 26 Graves disease is a condition that affects the function of the thyroid, which is a butterfly-shaped gland in the lower neck. The thyroid makes hormones that help regulate a wide variety of critical body functions. For example, thyroid hormones influence growth and development, body temperature, heart rate, menstrual cycles, and weight. In people with Graves disease, the thyroid is overactive and makes more hormones than the body needs. The condition usually appears in mid-adulthood, although it may occur at any age.

Wikipedia : 77 Graves'' disease, also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid.... more...

Related Diseases for Graves' Disease

Diseases in the Graves' Disease family:

Graves Disease 1 Graves Disease 2

Diseases related to Graves' Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 456)
# Related Disease Score Top Affiliating Genes
1 graves disease 1 34.0 DIO2 GRD1 SERPINA7 TG TPO TSHR
2 myxedema 32.8 CTLA4 TG TPO TSHR
3 hyperthyroidism 32.4 CTLA4 LMOD1 SERPINA7 TG TPO TSHR
4 thyroiditis 31.4 CTLA4 PTPN22 SERPINA7 TG TPO TSHR
5 goiter 31.4 SERPINA7 TG TPO TSHR
6 multinodular goiter 31.1 TG TPO TSHR
7 myasthenia gravis 31.0 CTLA4 IFNG IL4
8 struma ovarii 31.0 TG TSHR
9 hypothyroidism 31.0 CTLA4 DIO2 SERPINA7 TG TPO TSHR
10 plummer's disease 31.0 ICAM1 TG TPO
11 nodular goiter 31.0 ICAM1 TG TPO TSHR
12 papillary carcinoma 30.9 TG TPO TSHR
13 subacute thyroiditis 30.9 SERPINA7 TG TPO TSHR
14 hashimoto thyroiditis 30.9 CD40 CTLA4 ICAM1 IFNG IL4 PTPN22
15 celiac disease 1 30.6 CTLA4 HLA-DQA1 PTPN22 TG TPO
16 uveitis 30.5 CTLA4 ICAM1 IFNG IL4
17 hashimoto encephalopathy 30.5 TPO TSHR
18 benign struma ovarii 30.5 TG TSHR
19 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.5 CTLA4 IFNG PTPN22 TG TPO TSHR
20 thyroid cancer, nonmedullary, 2 30.4 DIO2 LMOD1 TG TPO TSHR
21 goiter, multinodular 1, with or without sertoli-leydig cell tumors 30.4 TG TPO
22 nontoxic goiter 30.4 SERPINA7 TG TPO TSHR
23 differentiated thyroid carcinoma 30.4 TG TPO TSHR
24 autoimmune disease 30.3 CD40 CTLA4 FCRL3 IFNG IL4 PTPN22
25 rheumatoid arthritis 30.3 CTLA4 FCRL3 HLA-DQA1 ICAM1 IFNG IL4
26 postsurgical hypothyroidism 30.2 TG TSHR
27 alopecia areata 30.2 CTLA4 ICAM1 IFNG PTPN22
28 congenital hypothyroidism 30.1 SERPINA7 TG TPO TSHR
29 systemic lupus erythematosus 30.1 CD40 CTLA4 FCRL3 HLA-DQA1 ICAM1 IFNG
30 multiple sclerosis 30.1 CD40 CTLA4 FCRL3 ICAM1 IFNG IL4
31 orbital plasma cell granuloma 30.0 CTLA4 TSHR
32 toxic diffuse goiter 30.0 DIO2 SERPINA7 TG TPO TSHR
33 hypothyroidism, congenital, nongoitrous, 2 30.0 SERPINA7 TG TSHR
34 hyperthyroxinemia 30.0 SERPINA7 TPO TSHR
35 keratoconjunctivitis 30.0 ICAM1 IFNG IL4
36 diabetes mellitus, insulin-dependent 29.9 CTLA4 HLA-DQA1 IFNG IL4 PTPN22 TG
37 asthma 29.4 CD40 HLA-DQA1 ICAM1 IFNG IL16 IL4
38 graves disease x-linked 1 12.3
39 graves disease 2 12.2
40 pediatric-onset graves disease 12.1
41 exophthalmos 11.4
42 digeorge syndrome 11.3
43 thyrotoxic periodic paralysis 1 11.3
44 thyrotoxic periodic paralysis 2 11.3
45 endocrine exophthalmos 11.3
46 hyperthyroidism, nonautoimmune 11.3
47 autoimmune thyroid disease 3 11.2
48 myopathy - thyrotoxic 11.2
49 velocardiofacial syndrome 11.0
50 autoimmune thyroid disease 2 11.0

Graphical network of the top 20 diseases related to Graves' Disease:



Diseases related to Graves' Disease

Symptoms & Phenotypes for Graves' Disease

MGI Mouse Phenotypes related to Graves' Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.13 CD40 CTLA4 DIO2 HLA-DQA1 ICAM1 IFNG
2 hematopoietic system MP:0005397 10.07 CD40 CTLA4 HLA-DQA1 ICAM1 IFNG IGF1R
3 digestive/alimentary MP:0005381 9.97 CTLA4 DIO2 ICAM1 IFNG IGF1R IL4
4 homeostasis/metabolism MP:0005376 9.93 CD40 CTLA4 DIO2 ICAM1 IFNG IGF1R
5 immune system MP:0005387 9.77 CD40 CTLA4 HLA-DQA1 ICAM1 IFNG IGF1R
6 skeleton MP:0005390 9.28 CD40 CTLA4 DIO2 IFNG IGF1R IL4

Drugs & Therapeutics for Graves' Disease

Drugs for Graves' Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 189)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propylthiouracil Approved, Investigational Phase 4,Phase 3,Phase 2 51-52-5 657298
2
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
3
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 302-25-0
4
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Not Applicable 2921-57-5
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
7
Iodine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7553-56-2 807
8
Triamcinolone Approved, Vet_approved Phase 4,Not Applicable 124-94-7 31307
9
Acetylcholine Approved, Investigational Phase 4,Phase 2,Phase 3 51-84-3 187
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1 50-02-2 5743
11
Methimazole Approved Phase 4,Phase 1,Phase 2,Not Applicable 60-56-0 1349907
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 1 1177-87-3
13
Propranolol Approved, Investigational Phase 4,Phase 3,Not Applicable 525-66-6 4946
14
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
15
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
16
Dinoprost tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
17
Dinoprost Approved, Investigational Phase 4 551-11-1 5283078
18
Bimatoprost Approved, Investigational Phase 4,Phase 3,Early Phase 1 155206-00-1 5311027
19
leucovorin Approved Phase 4,Not Applicable 58-05-9 143 6006
20
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
21
Methotrexate Approved Phase 4,Not Applicable 1959-05-2, 59-05-2 126941
22
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-30-3 6037
24
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Phase 3,Not Applicable 2920-86-7
25 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
28 Antithyroid Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
29 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Protective Agents Phase 4,Phase 2,Phase 3,Not Applicable
31 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Methylprednisolone Acetate Phase 4,Phase 2,Phase 3,Not Applicable
34 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Prednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
39 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Not Applicable
41 Anti-Infective Agents, Local Phase 4,Phase 2,Phase 3,Not Applicable
42 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Micronutrients Phase 4,Phase 2,Phase 3,Not Applicable
44 Nutrients Phase 4,Phase 2,Phase 3,Not Applicable
45 Trace Elements Phase 4,Phase 2,Phase 3,Not Applicable
46 cadexomer iodine Phase 4,Phase 2,Phase 3,Not Applicable
47 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Not Applicable
48 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Triamcinolone hexacetonide Phase 4,Not Applicable
50 triamcinolone acetonide Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 136)
# Name Status NCT ID Phase Drugs
1 The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy Unknown status NCT01056419 Phase 4 Propylthiouracil
2 A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy Unknown status NCT01969019 Phase 4 methylprednisolone, prednisone
3 Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease Completed NCT00946296 Phase 4 Potassium Iodide
4 Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone Completed NCT00917241 Phase 4 MMI combined with IID;MMI
5 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4 Diclofenac;Methimazole;L-thyroxin;Propranolol;Metoprolol
6 Antithyroid Drugs During Radioiodine Therapy Completed NCT00150137 Phase 4 Methimazole
7 Block-replacement Therapy During Radioiodine Therapy Completed NCT00150124 Phase 4 MTZ+LT4;Methimazole
8 Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Completed NCT02059655 Phase 4 Bimatoprost;Eye drop solution
9 Liver Function After Intravenous Methylprednisolone Administration Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
10 Is the Routine Pressure Dressing After Thyroidectomy Necessary? Completed NCT00400465 Phase 4
11 99Tc-MDP for Thyroid-Associated Ophthalmopathy Completed NCT03948191 Phase 4 Methylprednisolone;99Tc-MDP(99Technetium-Methylenediphosphonate Injection)
12 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
13 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4 subconjunctival triamcinolone injection
14 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
15 Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial Recruiting NCT03107078 Phase 4 Glucocorticoids
16 Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Recruiting NCT01738243 Phase 4 Hyaluronic Acid Gel injection;Saline injection
17 A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy Not yet recruiting NCT03098225 Phase 4 Methylprednisolone
18 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Not yet recruiting NCT02339142 Phase 4 intravenous corticosteroids (methylprednisolone)
19 The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Withdrawn NCT01927406 Phase 4 Prostaglandin Analog;Timolol
20 Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction Withdrawn NCT01272414 Phase 4 Botulinum Toxin Type A;Saline injection
21 Early Levothyroxine Post Radioactive Iodine Unknown status NCT01950260 Phase 2, Phase 3 Levothyroxine
22 The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions Unknown status NCT01204359 Phase 3
23 Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy Unknown status NCT01809444 Phase 2, Phase 3 Prednisone+placebo of Doxycycline;Doxycycline+placebo of Prednisone
24 Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease Unknown status NCT00370734 Phase 2, Phase 3 Botulinum toxin A injection
25 Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism Completed NCT01039818 Phase 3
26 Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance Completed NCT01295333 Phase 3 the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation;The initiation of LT4 as soon as the first biological signs of hypothyroidism.
27 Trial of Rituximab for Graves' Ophthalmopathy Completed NCT00595335 Phase 2, Phase 3 Rituximab;Saline;Methylprednisolone
28 Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues Completed NCT02155049 Phase 3 bimatoprost 0.03%
29 Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) Completed NCT01297699 Phase 3 Tocilizumab (RoActemra®);Sterile 0.9% Sodium Chloride
30 Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism Recruiting NCT03303053 Phase 3 Cholestyramine Powder 4g;Prednisolone;Standard treatment
31 Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy Recruiting NCT03066076 Phase 3 Antithyroid Drug
32 Bupivacaine Injection of Eye Muscles to Treat Strabismus Recruiting NCT01616108 Phase 2, Phase 3 Bupivacaine
33 Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS) Recruiting NCT03131726 Phase 3 Simvastatin 40mg
34 The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy Recruiting NCT01579539 Phase 3 Methylprednisolone;Esomeprazole
35 Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study Active, not recruiting NCT03298867 Phase 3
36 Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study Enrolling by invitation NCT03461211 Phase 3
37 The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease Not yet recruiting NCT02422368 Phase 2, Phase 3 Methylprednisolone + ASTED;Methylprednisolone +Placebo
38 The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) Not yet recruiting NCT02393183 Phase 2, Phase 3 ASTED
39 Role of the Microbiome in Graves' Orbitopathy Unknown status NCT02373995 Phase 1, Phase 2
40 Doxycycline Treatment in Mild Graves' Orbitopathy Unknown status NCT02203682 Phase 2 Doxycycline;placebo
41 Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients Completed NCT02993302 Phase 2 1α-D3;Placebos
42 A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease Completed NCT02713256 Phase 2 CFZ533
43 Radioactive Iodide Therapy for Pediatric Graves' Disease Completed NCT01269749 Phase 2 ATD Group
44 Rituximab in the Treatment of Graves' Disease Completed NCT00150111 Phase 1, Phase 2 Methimazole;Rituximab
45 rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter Completed NCT00145366 Phase 2 Recombinant human thyrotropin (Thyrogen)
46 Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy Completed NCT00424151 Phase 1, Phase 2 Rituximab
47 Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Completed NCT01727973 Phase 1, Phase 2 Doxycycline
48 Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease Completed NCT01868997 Phase 2 teprotumumab;normal saline
49 Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy ( GO ) Recruiting NCT03922321 Phase 2 RVT-1401 (Administered via subcutaneous injection)
50 Celecoxib for Thyroid Eye Disease Recruiting NCT02845336 Phase 2 Celecoxib;artificial tears

Search NIH Clinical Center for Graves' Disease

Cochrane evidence based reviews: graves disease

Genetic Tests for Graves' Disease

Genetic tests related to Graves' Disease:

# Genetic test Affiliating Genes
1 Graves Disease 30

Anatomical Context for Graves' Disease

MalaCards organs/tissues related to Graves' Disease:

42
Thyroid, Eye, T Cells, Bone, Heart, Skin, B Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Graves' Disease:

20
Thyroid Gl

Publications for Graves' Disease

Articles related to Graves' Disease:

(show top 50) (show all 3558)
# Title Authors Year
1
Efficacy of 99mTc-DTPA SPECT/CT in diagnosing Orbitopathy in graves' disease. ( 30658624 )
2019
2
Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy. ( 30688164 )
2019
3
Managing thymic enlargement in Graves' disease. ( 30703065 )
2019
4
Graves' Disease with Pancytopenia and Hepatic Dysfunction: A Rare Case Presentation. ( 30713378 )
2019
5
A Case of Violent Suicide Attempt in a Context of Myxedema Psychosis following Radioiodine Treatment in a Patient with Graves' Disease. ( 30729057 )
2019
6
Erratic movement disorders disclosing Graves' disease and paralleling thyroid function but not autoantibody levels. ( 30761931 )
2019
7
See-Saw Relationship and its Reversal after Immunotherapy in a Case of Graves' Disease with Coexisting Myasthenia Gravis. ( 30765989 )
2019
8
Prevalence of diabetes and presence of autoantibodies against zinc transporter 8 and glutamic decarboxylase at diagnosis and at follow up of Graves' disease. ( 30783963 )
2019
9
Thyroid vascularization is an important ultrasonographic parameter in untreated Graves' disease patients. ( 30792955 )
2019
10
Linkage Analysis of the Chromosome 5q31-33 Region Identifies JAKMIP2 as a Risk Factor for Graves' Disease in the Chinese Han Population. ( 30796769 )
2019
11
A case report of 131I therapy for Graves' disease patient with hemiagenesis. ( 30813185 )
2019
12
Upregulated tissue expression of T helper (Th) 17 pathogenic interleukin (IL)-23 and IL-1β in Hashimoto's thyroiditis but not in Graves' disease. ( 30814438 )
2019
13
Serum autotaxin levels are associated with Graves' disease. ( 30814442 )
2019
14
The value of total thyroidectomy as the definitive treatment for Graves' disease: A single centre experience of 594 cases. ( 30815364 )
2019
15
A Modifying Autoantigen in Graves' Disease. ( 30822352 )
2019
16
Progressive stenosis and radiological findings of vasculitis over the entire internal carotid artery in moyamoya vasculopathy associated with graves' disease: a case report and review of the literature. ( 30825882 )
2019
17
Can a patient-tailored treatment approach for Graves' disease reduce mortality? ( 30827828 )
2019
18
Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study. ( 30827829 )
2019
19
Standardized Uptake Value Using Thyroid Quantitative SPECT/CT for the Diagnosis and Evaluation of Graves' Disease: A Prospective Multicenter Study. ( 30834273 )
2019
20
Proteinuria in a patient with Graves' disease: Questions. ( 30843109 )
2019
21
Proteinuria in a patient with Graves' disease: Answers. ( 30843111 )
2019
22
Graves' disease as a first autoimmune manifestation of a stiff person syndrome. ( 30846197 )
2019
23
Endothelial Cell Growth Promoting Activity in Graves' Disease Sera is Neutralized by Anti-Basic Fibroblast Growth Factor Antibodies in Patients with Fat Expansive but Not Infiltrative Orbitopathy. ( 30854171 )
2019
24
Papillary thyroid carcinoma in cervical lymph nodes with vanished thyroid gland after ablation of Graves' disease by radioactive iodine. ( 30854863 )
2019
25
Long-term monitoring of Graves’ disease in children and adolescents: a single-center experience ( 30862149 )
2019
26
Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience. ( 30862763 )
2019
27
Muscle performance and postural stability are reduced in patients with newly diagnosed Graves' disease. ( 30880636 )
2019
28
Factors Predicting Time to TSH Normalization and Persistence of TSH Suppression After Total Thyroidectomy for Graves' Disease. ( 30881342 )
2019
29
Serum levels of insulin-like growth factor 1 are negatively associated with log transformation of thyroid-stimulating hormone in Graves' disease patients with hyperthyroidism or subjects with euthyroidism: A prospective observational study. ( 30882687 )
2019
30
Decreased circulating levels of ANGPTL8 in Graves' disease patients. ( 30900216 )
2019
31
Graves' Disease: Can It Be Cured? ( 30912336 )
2019
32
Association between vitamin D receptor gene polymorphisms and Graves' disease: a systematic review and meta-analysis. ( 30924084 )
2019
33
Association of PTPN22 polymorphism and its correlation with Graves' disease susceptibility in Polish adult population-A preliminary study. ( 30938100 )
2019
34
Increased IL-35 in the circulation of patients with Graves' disease. ( 30938833 )
2019
35
Circulating microRNA-144-3p and miR-762 are novel biomarkers of Graves' disease. ( 30949910 )
2019
36
Isolated leg tremor in a middle-aged woman: an unusual presenting symptom of Graves' disease. ( 30955162 )
2019
37
Association between the CD40 rs1883832 polymorphism and Graves' disease risk: a meta-analysis. ( 30956635 )
2019
38
Paraganglioma of the tongue with SDHB gene mutation in a patient with Graves' disease. ( 30997073 )
2019
39
Evaluation of Vitamin D Status and its Impact on Thyroid Related Parameters in New Onset Graves' Disease- A Cross-sectional Observational Study. ( 31016150 )
2019
40
Comparison of Five TSH-Receptor Antibody Assays in Graves' disease: results from an observational pilot study. ( 31023276 )
2019
41
Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients. ( 31024443 )
2019
42
Decreased expression of FcγRII in active Graves' disease patients. ( 31033004 )
2019
43
Long-term Methimazole Therapy in Juvenile Graves' Disease: A Randomized Trial. ( 31040197 )
2019
44
Unilateral Graves' Disease: The Lesser Known. ( 31040519 )
2019
45
Effect of IL-21 on the Balance of Th17 Cells/Treg Cells in the Pathogenesis of Graves' Disease. ( 31055979 )
2019
46
Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy. ( 31059842 )
2019
47
Intrathyroidal Thymic Tissue in an Adolescent with Graves' Disease: Case Report and Review of Current Literature. ( 31065395 )
2019
48
Finding the best effective way of treatment for rapid I-131 turnover Graves' disease patients: A randomized clinical trial. ( 31083231 )
2019
49
Possible participation of colloid antigen 2 and abhormone (IgG with hormone activity) for the etiology of Graves' disease. ( 31088643 )
2019
50
A Case of Gitelman's Syndrome that was difficult to distinguish from Hypokalemic Periodic Paralysis due to Graves' Disease. ( 31105122 )
2019

Variations for Graves' Disease

Expression for Graves' Disease

Search GEO for disease gene expression data for Graves' Disease.

Pathways for Graves' Disease

Pathways related to Graves' Disease according to KEGG:

38
# Name Kegg Source Accession
1 Autoimmune thyroid disease hsa05320

Pathways related to Graves' Disease according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1 12.34 CTLA4 IFNG IL4 PTPN22
2
Show member pathways
12.07 DIO2 ICAM1 IFNG IL4
3
Show member pathways
12.02 CD40 CTLA4 HLA-DQA1 ICAM1 IFNG IL4
4
Show member pathways
11.98 CD40 HLA-DQA1 IFNG IL4
5 11.79 ICAM1 IFNG IL4
6 11.79 CD40 CTLA4 HLA-DQA1 ICAM1
7 11.6 ICAM1 IFNG IL4
8
Show member pathways
11.55 CTLA4 IFNG IL4
9 11.5 CTLA4 HLA-DQA1 PTPN22
10 11.48 CD40 IFNG IL4
11 11.42 CTLA4 HLA-DQA1 ICAM1 IFNG
12 11.23 CD40 ICAM1 IFNG
13 10.95 CD40 IFNG IL4
14 9.91 TG TPO TSHR

GO Terms for Graves' Disease

Cellular components related to Graves' Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 CD40 FCRL3 ICAM1 TPO TSHR
2 integral component of plasma membrane GO:0005887 9.17 CD40 CTLA4 HLA-DQA1 ICAM1 IGF1R TPO

Biological processes related to Graves' Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.63 CTLA4 HLA-DQA1 IFNG IGF1R IL16 IL4
2 interferon-gamma-mediated signaling pathway GO:0060333 9.54 HLA-DQA1 ICAM1 IFNG
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.5 CD40 IFNG IL4
4 regulation of NIK/NF-kappaB signaling GO:1901222 9.49 PTPN22 UACA
5 regulation of regulatory T cell differentiation GO:0045589 9.48 CTLA4 IFNG
6 thyroid hormone generation GO:0006590 9.46 DIO2 TPO
7 positive regulation of isotype switching to IgG isotypes GO:0048304 9.43 CD40 IL4
8 positive regulation of B cell proliferation GO:0030890 9.43 CD40 FCRL3 IL4
9 thyroid hormone metabolic process GO:0042403 9.4 DIO2 TG
10 positive regulation of cold-induced thermogenesis GO:0120162 9.26 DIO2 IGF1R IL4 TSHR
11 hormone biosynthetic process GO:0042446 8.8 DIO2 TG TPO

Sources for Graves' Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....